Книги фарма 2 / Bertram G. Katzung-Basic & Clinical Pharmacology(9th Edition)

			Methadone: [P] Decreased serum
			methadone levels; withdrawal
			symptoms.
			Mexiletine: [NE] Decreased serum
			mexiletine levels.
			Quinidine: [P] Decreased serum
			quinidine levels.
			Theophylline: [NE] Decreased serum
			theophylline levels.
			Verapamil: [NE] Decreased serum
			verapamil levels.
			See also Calcium channel blockers,
			Cyclosporine, Estrogens.
			Drugs that inhibit phenytoin
			metabolism:
			Amiodarone: [P] Increased serum
			phenytoin; possible reduction in serum
			amiodarone.
			Capecitabine: [NE] Increased serum
			phenytoin.
			Chloramphenicol: [P] Increased
			serum phenytoin.
			Felbamate: [P] Increased serum
			phenytoin.
			Fluorouracil: [NE] Increased serum
			phenytoin.
			Fluvoxamine: [NE] Increased serum
			phenytoin.
			Isoniazid: [NP] Increased serum
			phenytoin; problem primarily with slow
			acetylators of isoniazid.
			Miconazole: [P] Increased serum
			phenytoin.
			Ticlopidine: [NP] Increased serum
			phenytoin.
			See also Cimetidine; Disulfiram;
			Phenylbutazone.
			Drugs that enhance phenytoin
			metabolism:
			Rifampin: [P] Decreased serum
			phenytoin levels.
Pimozide	Susceptible to CYP3A4 inhibitors;		Clarithromycin: [NE] Decreased
	may exhibit additive effects with		pimozide metabolism.

				other agents that prolong QTc			Erythromycin: [NE] Decreased
				interval.			pimozide metabolism
							Nefazodone: [NE] Decreased
							pimozide metabolism.
							See also Azole antifungals,
							Cyclosporine.
	Potassium-sparing			Additive effects with other agents			ACE inhibitors: [NE] Additive
	diuretics			increasing serum potassium			hyperkalemic effect.
	(amiloride,			concentration. May alter renal			Potassium supplements: [P] Additive
	spironolactone,			excretion of substances other than
							hyperkalemic effect; especially a
	triamterene)			potassium (eg, digoxin, hydrogen			problem in presence of renal
				ions).
							impairment.
							See also Digitalis glycosides;
							Nonsteroidal anti-inflammatory drugs.
	Probenecid			Interference with renal excretion of			Clofibrate: [P] Reduced glucuronide
				drugs that undergo active tubular			conjugation of clofibric acid.
				secretion, especially weak acids.			Methotrexate: [P] Decreased renal
				Inhibition of glucuronide
							methotrexate excretion; possible
				conjugation of other drugs.
							methotrexate toxicity.
							Penicillin: [P] Decreased renal
							penicillin excretion.
							Salicylates: [P] Decreased uricosuric
							effect of probenecid (interaction
							unlikely with less than 1.5 g of
							salicylate daily).
	Quinidine			Metabolism inducible. Inhibits			Acetazolamide: [P] Decreased renal
				CYP2D6. Renal excretion			quinidine excretion due to increased
				susceptible to changes in urine pH.			urinary pH; elevated serum quinidine.
				Additive effects with other agents			Amiodarone: [NE] Increased serum
				that prolong the QTc interval.
							quinidine levels; mechanism not
							established.
							Kaolin-pectin: [NE] Decreased
							gastrointestinal absorption of quinidine.
							Rifampin: [P] Increased hepatic
							quinidine metabolism.
							Thioridazine: [NE] Decreased
							thioridazine metabolism; additive
							prolongation of QTc interval.
							See also Anticoagulants, oral;
							Antidepressants, tricyclic; Barbiturates;
							Cimetidine; Digitalis glycosides;
							Phenytoin.
	Quinolone			Susceptible to inhibition of			Caffeine: [P] Ciprofloxacin, enoxacin,
	antibiotics			gastrointestinal absorption. Some			pipedemic acid, and to a lesser extent,

				quinolones inhibit CYP1A2.			norfloxacin, inhibit caffeine
							metabolism.
							Sucralfate: [HP] Reduced
							gastrointestinal absorption of
							ciprofloxacin, norfloxacin, and probably
							other quinolones.
							Theophylline: [P] Ciprofloxacin,
							enoxacin, and, to a lesser extent,
							norfloxacin inhibit theophylline
							metabolism; gatifloxacin, levofloxacin,
							lomefloxacin, ofloxacin, and
							sparfloxacin appear to have little effect.
							See also Antacids; Anticoagulants, oral.
	Rifampin			Induction of hepatic microsomal			Corticosteroids: [P] Increased
				drug-metabolizing enzymes.			corticosteroid hepatic metabolism;
							reduced corticosteroid effect.
							Mexiletine: [NE] Increased mexiletine
							metabolism; reduced mexiletine effect.
							Sulfonylurea hypoglycemics: [P]
							Increased hepatic metabolism of
							tolbutamide and probably other
							sulfonylureas metabolized by the liver
							(including chlorpropamide).
							Theophylline: [P] Increased
							theophylline metabolism; reduced
							theophylline effect.
							See also Anticoagulants, oral; Azole
							antifungals; Beta-adrenoceptor
							blockers; Calcium channel blockers;
							Cyclosporine; Digitalis glycosides;
							Estrogens.
	Salicylates			Interference with renal excretion of			Carbonic anhydrase inhibitors: [NE]
				drugs that undergo active tubular			Increased acetazolamide serum
				secretion. Salicylate renal excretion			concentrations; increased salicylate
				dependent on urinary pH when			toxicity due to decreased blood pH.
				large doses of salicylate used.			Corticosteroids: [P] Increased
				Aspirin (but not other salicylates)
							salicylate elimination; possible additive
				interferes with platelet function.
							toxic effect on gastric mucosa.
				Large doses of salicylates have
							Heparin: [NE] Increased bleeding
				intrinsic hypoglycemic activity.
				Salicylates may displace drugs			tendency with aspirin, but probably not
				from plasma protein binding sites.			with other salicylates.
							Methotrexate: [P] Decreased renal
							methotrexate clearance; increased
							methotrexate toxicity (primarily at
							anticancer doses).

							Sulfinpyrazone: [HP] Decreased
							uricosuric effect of sulfinpyrazone
							(interaction unlikely with less than 1.5 g
							of salicylate daily).
							See also Antacids; Anticoagulants, oral;
							Probenecid.
	Theophylline			Susceptible to inhibition of hepatic			Benzodiazepines: [NE] Inhibition of
				metabolism by CYP1A2.			benzodiazepine sedation.
				Metabolism inducible.			Diltiazem: [P] Decreased theophylline
							metabolism by CYP1A3.
							Clarithromycin: [NE] Decreased
							theophylline metabolism.
							Erythromycin: [P] Decreased
							theophylline metabolism.
							Fluvoxamine: [P] Decreased
							theophylline metabolism.
							Smoking: [HP] Increased theophylline
							metabolism.
							Tacrine: [P] Decreased theophylline
							metabolism.
							Ticlopidine: [NE] Decreased
							theophylline metabolism.
							Troleandomycin: [P] Decreased
							theophylline metabolism.
							Verapamil: [P] Decreased theophylline
							metabolism.
							Zileuton: [P] Decreased theophylline
							metabolism.
							See also Barbiturates; Carbamazepine;
							Cimetidine; Lithium; Phenytoin;
							Quinolones; Rifampin.